The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Abstract
PURPOSE: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS. PATIENTS AND METHODS: A randomized controlled trial was undertaken in 191 patients with MDS to compare Aza C (75 mg/m 2/d subcutaneously for 7 days every 28 days) with supportive care. MDS was defined by French-American-British criteria. New rigorous response criteria were applied. Both arms received transfusions and antibiotics as required. Patients in the supportive care arm whose disease worsened were permitted to cross over to Aza C. RESULTS: Responses occurred in 60% of patients on the Aza C arm (7% complete response, 16% partial response, 37% improved) compared with 5% (improved) receiving supportive care (P < .001). Median time to leukemic transformation or death was 21 months for Aza C versus 13 months for supportive care (P = .007). Transformation to acute myelogenous leukemia occurred as the first event in 15% of patients on the Aza C arm and in 38% receiving supportive care (P = .001). Eliminating the confounding effect of early cross-over to Aza C, a landmark analysis after 6 months showed median survival of an additional 18 months for Aza C and 11 months for supportive care (P = .03). Quality-of-life assessment found significant major advantages in physical function, symptoms, and psychological state for patients initially randomized to Aza C. CONCLUSION: Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care. Aza C provides a new treatment option that is superior to supportive care for patients with the MDS subtypes and specific entry criteria treated in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
DNA Methylation and Gene Function
Razin, A., & Riggs, A. D. (1980) · Science · doi:10.1126/science.6254144 · Cited by 2,071
Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine
Taylor, S. M., & Jones, P. A. (1979) · Cell · doi:10.1016/0092-8674(79)90317-9 · Cited by 1,100
Pattern-Mixture Models for Multivariate Incomplete Data
Little, R. J. A. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10594302 · Cited by 1,035
Kernan, N. A., Bartsch, G., Ash, R. C., Beatty, P. G., Champlin, R., Filipovich, A., Gajewski, J., Hansen, J. A., Henslee-Downey, J., McCullough, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303043280901 · Cited by 825
DNA methylation and gene expression
Razin, A., & Cedar, H. (1991) · Microbiological Reviews · doi:10.1128/mmbr.55.3.451-458.1991 · Cited by 771
Creusot, F., Acs, G., & Christman, J. K. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68144-5 · Cited by 564
5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+Thalassemia
Ley, T. J., DeSimone, J., Anagnou, N. P., Keller, G. H., Humphries, R. K., Turner, P. H., Young, N. S., Heller, P., & Nienhuis, A. W. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212093072401 · Cited by 490
Kornblith, A. B., Herndon, J. E., Silverman, L. R., Demakos, E. P., Odchimar-Reissig, R., Holland, J. F., Powell, B. L., DeCastro, C., Ellerton, J., Larson, R. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.044 · Cited by 419
Self-citationMIXTURE MODELS FOR THE JOINT DISTRIBUTION OF REPEATED MEASURES AND EVENT TIMES
HOGAN, J. W., & LAIRD, N. M. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970215)16:3<239::aid-sim483>3.0.co;2-x · Cited by 339
Antin, J. H., Br, S., Holmes, W., & Rosenthal, D. (1988) · Blood · doi:10.1182/blood.v72.2.705.705 · Cited by 298
Ganser, A., Volkers, B., Greher, J., Ottmann, O., Walther, F., Becher, R., Bergmann, L., Schulz, G., & Hoelzer, D. (1989) · Blood · doi:10.1182/blood.v73.1.31.31 · Cited by 292
Charache, S., Dover, G., Smith, K., Talbot, C. C., Moyer, M., & Boyer, S. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.15.4842 · Cited by 275
1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells.
Koeffler, H. P., Hirji, K. F., & Itri, L. M. (1985) · PubMed · Cited by 270
Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes
Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T., & Murate, T. (1997) · Blood · doi:10.1182/blood.v90.4.1403 · Cited by 269
Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia.
Li, L. H., Olin, E. J., Buskirk, H. H., & REINEKE, L. M. (1970) · PubMed · Cited by 263
Miller, J., Arthur, D., Litz, C., Neglia, J., Miller, W., & Weisdorf, D. (1994) · Blood · doi:10.1182/blood.v83.12.3780.3780 · Cited by 234
Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases
Foucar, K., Langdon, R. M., Armitage, J. O., Olson, D. B., & Carroll, T. J. (1985) · Cancer · Cited by 231
Estey, E. H., Thall, P. F., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M. J., Andreeff, M., & Freireich, E. (1999) · Blood · doi:10.1182/blood.v93.8.2478 · Cited by 224
Improved methodology for analyzing local and distant recurrence.
Gelman, R., Gelber, R., Henderson, I. C., Coleman, C. N., & Harris, J. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.548 · Cited by 224
Cheson, B. D., Jasperse, D. M., Simon, R., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 211
Felsenfeld, G., & McGhee, J. (1982) · Nature · doi:10.1038/296602a0 · Cited by 209
Kerkhofs, H., Hermans, J., Haak, H. L., & Leeksma, C. H. W. (1987) · British Journal of Haematology · doi:10.1111/j.1365-2141.1987.tb06138.x · Cited by 192
Christman, J. K., Mendelsohn, N., Herzog, D., & Schneiderman, N. (1983) · PubMed · Cited by 185
Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders
Koeffler, H., Heitjan, D. F., Mertelsmann, R., Kolitz, J., Schulman, P., Itri, L. M., Günter, P., & Besa, E. C. (1988) · Blood · doi:10.1182/blood.v71.3.703.703 · Cited by 142
Myelodysplastic syndromes: a study of 101 cases according to the FAB classification
Vallespı́, T., Torrabadella, M., Julià, A., Irriguible, D., Jaén, A., Acebedo, G., & Triginer, J. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb04063.x · Cited by 130
Andreeff, M., Stone, R. M., Michaeli, J., Cw, Y., Tong, W., Sogoloff, H., Ervin, T. J., Kufe, D. W., Rifkind, R. A., & Marks, P. (1992) · Blood · doi:10.1182/blood.v80.10.2604.2604 · Cited by 124
Self-citationMiller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1993) · Annals of Hematology · doi:10.1007/bf01697631 · Cited by 114
Miller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1992) · Annals of Hematology · doi:10.1007/bf01703109 · Cited by 113
Erythropoietin-Induced Activation of STAT5 Is Impaired in the Myelodysplastic Syndrome
Hoefsloot, L. H., Amelsvoort, M. P.-V., Broeders, L., van der Plas, D. C., van Lom, K., Hoogerbrugge, H., Touw, I. P., & Löwenberg, B. (1997) · Blood · doi:10.1182/blood.v89.5.1690 · Cited by 93
Coutinho, L. H., Will, A., Radford, J. A., Schirò, R., Testa, N. G., & Dexter, T. M. (1990) · Blood · doi:10.1182/blood.v75.11.2118.2118 · Cited by 87
Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine
Gambari, R., SENNO, L. D., Barbieri, R., Viola, L., Tripodi, M., Raschellà, G., & Fantoni, A. (1984) · Cell Differentiation · doi:10.1016/0045-6039(84)90033-2 · Cited by 65
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
Kurzrock, R., Estey, E. H., & Talpaz, M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1489 · Cited by 61
Ab, G., Leyland-Jones, B., Hg, C., Davies, B., & Df, H. (1987) · PubMed · Cited by 56
Mittelman, M., Gardyn, J., Carmel, M., Malovani, H., Barak, Y., & Nir, U. (1996) · Leukemia Research · doi:10.1016/0145-2126(96)00002-1 · Cited by 40
Backx, B., Broeders, L., Lh, H., Wognum, B., & Löwenberg, B. (1996) · PubMed · Cited by 35
High-Risk Myelodysplastic Syndromes and Hypermethylation of the p15Ink4BGene
Uchida, T., Kinoshita, T., Hotta, T., & Murate, T. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809059242 · Cited by 22
Kornblith, A. B., & Jc, H. (1996) · PubMed · Cited by 22
Self-citationDover, G. J., Charache, S., Nora, R. E., & Boyer, S. H. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb17191.x · Cited by 15
Cited by
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationFenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Metadata
- Authors
- Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., Ellerton, J., Larson, R. A., Schiffer, C. A., & Holland, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-05-15
- Volume
- 20
- Issue
- 10
- Pages
- 2429-2440
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106584820
- Cited by
- 1,825
- References
- 46
- FWCI
- 26.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.